Glycated Haemoglobin Versus Serum Fructosamine in Assessing Glycaemic Control Amongst Type 2 Diabetes Mellitus Patients With Haemoglobin Variants: A Systematic Review
BioMed Research International · 2026-01 · 2026 (1)
DOI: 10.1155/bmri/9298499 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BioMed Research International, online erschienen am 14.11.2026. Verfasst von Edward Morkporkpor Adela und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Science, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana, ucc.edu.gh. Hauptthemen laut MEDLINE: Fructosamine, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Glycemic Control. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Haemoglobin variants lead to shortened red cell lifespan and may affect the reliability of HbA1c. This review synthesised evidence on the validity, reliability and practical utility of HbA1c versus serum fructosamine (SF) in Type 2 diabetes mellitus (T2DM) adults with haemoglobinopathies and mapped assay‐ and phenotype‐specific interferences. A systematic review was conducted on articles indexed in PubMed, Ovid MEDLINE and Scopus following PRISMA 2020 guidelines. The protocol was prospectively registered on PROSPERO (ID: CRD420251128494). Seventeen studies out of 85 records met the inclusion criteria. HbA1c appeared to remain valid in heterozygous carriers but was unreliable in individuals with homozygous or compound variants, particularly when measured using ion‐exchange HPLC. SF may provide an alternative measure of glycaemic status when HbA1c was invalidated by haemoglobin variants. Large cohort evidence showed that fructosamine and glycated albumin maintained strong correlations with fasting glucose and continuous glucose monitoring (CGM) indices, achieving high diagnostic accuracy for uncontrolled glycaemia. HbA1c appears appropriate for most heterozygous haemoglobinopathy carriers using NGSP/IFCC‐aligned assays, whereas fructosamine and glycated albumin could be reliable short‐term alternatives in homozygous or compound variants, contingent on albumin status. Standardised, multicentre accuracy studies across assay families and genotypes are needed to refine guidance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory Science, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana, ucc.edu.gh.
- Department of Family Medicine, Cape Coast Teaching Hospital, Cape Coast, Ghana, ccthghana.org.
- Department of Immunology and Microbiology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana, ucc.edu.gh.
ORCID-Profile: Edward Morkporkpor Adela, Richard Kojo Yankah, George Nkrumah Osei, Wisdom Agbotey, Patrick Adu
Zitieren
APA
Adela, E. M., Yankah, R. K., Osei, G. N., Agbotey, W., & Adu, P. (2026). Glycated Haemoglobin Versus Serum Fructosamine in Assessing Glycaemic Control Amongst Type 2 Diabetes Mellitus Patients With Haemoglobin Variants: A Systematic Review. BioMed Research International, 2026(1). https://doi.org/10.1155/bmri/9298499
Vancouver
Adela EM, Yankah RK, Osei GN, Agbotey W, Adu P. Glycated Haemoglobin Versus Serum Fructosamine in Assessing Glycaemic Control Amongst Type 2 Diabetes Mellitus Patients With Haemoglobin Variants: A Systematic Review. BioMed Research International. 2026;2026(1). doi:10.1155/bmri/9298499
BibTeX
@article{Adela2026,
author = {Adela, Edward Morkporkpor and Yankah, Richard Kojo and Osei, George Nkrumah and Agbotey, Wisdom and Adu, Patrick},
title = {Glycated Haemoglobin Versus Serum Fructosamine in Assessing Glycaemic Control Amongst Type 2 Diabetes Mellitus Patients With Haemoglobin Variants: A Systematic Review},
journal = {BioMed Research International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/bmri/9298499}
}
EUVIMED